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Summary
Objectives: To compare frequency and patterns of hormone re-
placement therapy (HRT) between primary care patients and
the local community.
Methods: Comparison of data from a questionnaire survey of
107 peri- and postmenopausal patients in an academic primary
care clinic during 1998 to similar data from a sample (n=241) of
an ongoing annual epidemiological survey representative of
the general population.
Results: Mean age, menopause status, age of initiation of HRT,
and prior use of contraceptive pill were similar in both groups.
Current HRT use tended to be lower among patients in the
clinic than in the community. HRT users in the clinic were more
likely to have had a surgical menopause (34.4% vs. 16.1%,
p=0.04) and to have used hormones for shorter periods than in
the general population. Differences remained significant after
adjustment in multivariate analysis.
Conclusions: Compared to the general population, patterns of
HRT use in the outpatient clinic were more restrictive than re-
commendations on HRT that were published at the time. This 
is an example of how comparison of health issues between 
patients in medical care and a local epidemiological survey can
help to understand clinical practice.
Keywords: Hormone replacement therapy – Primary care –
Menopausal women – General population – Prevalence.
Hormone replacement therapy (HRT) is an important
health issue for postmenopausal women. Although initially
prescribed only for climacteric symptom relief, HRT rapidly
became a cornerstone in the prevention and treatment of
postmenopausal osteoporotic fractures (Ettinger et al.
1985). Evidence from observational studies suggested po-
tential substantial benefit of HRT in the primary and secon-
dary prevention of coronary heart disease (CHD) after the
menopause. Before 2002, experts recommended to counsel
all perimenopausal and postmenopausal women about the
benefits and risks of postmenopausal hormone prophylaxis.
The main potential benefits expected at the time were treat-
ment of symptoms of menopause, reduction of osteoporotic
fracture’ risk and reduction of coronary heart disease. These
benefits were balanced against the risks of an increase in
breast cancer and thromboembolic events. The American
College of Physicians added that women with a hysterec-
tomy would be likely to benefit from therapy (American
College of Physicians 1992; U.S. Preventive Services Task
Force 1996). However, recent randomised controlled trials
(Hulley et al. 1998; Rossouw et al. 2002) have shown that es-
trogen-progestin therapy increases the risks of stroke, ve-
nous thromboembolism and breast cancer after five years
without preventing CHD events. A recent study showed
similar findings for estrogen-alone therapy of women with
hysterectomy except the increased risk of breast cancer
(Women’s Health Initiative Randomized Controlled Trial
2004).
Prevalence of HRT use among middle-aged women varies
according to socio-economic, cultural, and medical factors
(Harris et al. 1999). In the USA, use in the general popula-
tion ranged between 11% and 38% with the highest pre-
valence among menopausal women who lived on the West
Coast (Brett & Madans 1997; Johannes et al. 1994; Harris 
et al. 1990; Derby et al. 1993; Cauley et al. 1990; Derby et al.
1995; Brown et al. 1999; Keating et al. 1999). Uptake was
lower in Europe ranging between 2% (Crosignani 1996;
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Moorhead et al. 1997; Oddens et al. 1994; Oddens & 
Boulet 1997) and 33% in Britain (Million Women Study
Collaborators 2002) and Norway (Bakken et al. 2001). 
Comparisons are difficult since studies were conducted at
different periods, however HRT use tended to steadily 
increase until 2002 (Derby et al. 1993; Johannes et al. 1994;
Moorhead et al. 1997; Mueller et al. 2002). Prevalence has
decreased substantially since that date (Hersh et al. 2004)
following recent findings and changes in recommendations
(U.S. Preventive Services Task Force 2002).
Primary care physicians are in an ideal, even if difficult, 
position when it comes to counselling menopausal patients
on hormone replacement among other health issues
(Stafford et al. 1997). In Switzerland, prescription of HRT 
is often considered a gynaecologist’s issue and we know very
little about practice in primary care. Therefore, we decided
to assess HRT counselling practices among primary care
trainee physicians in a University Hospital outpatient clinic.
We measured the prevalence and determinants of HRT use
among peri- and postmenopausal women. We compared our
findings with similar data from an ongoing epidemiological
survey of health indicators in the population of the area 
(Galobardes et al. 2003). Differences observed were likely to
reflect the physicians’ counselling practice in the field of HRT.
Methods
We studied HRT use in two samples of peri- and post-
menopausal women aged 45–65 years who were residents 
in the canton of Geneva, Switzerland. In November and 
December 1998, all female patients aged 45–65 years who
consulted at the General Internal Medicine outpatient clinic
of Geneva University Hospital were asked to complete an
anonymous self-administered questionnaire about repro-
ductive history and HRT use. The clinic is an ambulatory
care unit of the University Hospital which is open to all adult
patients in the population. Residents have three to five years
of clinical experience in internal medicine and remain one to
two years. There has been a tendency to over recruit patients
of a lower socio-economic status, for historical reasons.
The results were compared with data obtained in 1998 from
the “Health Mobile Epidemiological Unit” (BUJ Santé)
project. This is an ongoing annual community-based survey
of cardio-vascular risk factors among men and women aged
35–74 resident in the canton of Geneva, which is described
in detail elsewhere (Galobardes et al. 2003; Morabia et al.
1997). In brief, randomly selected residents received a mail
questionnaire about health status and behaviour and were
invited to bring the completed questionnaire to the “Health
Mobile Unit” or to offices at Geneva University Hospital. 
The self-completed questionnaire included closed questions,
which were identical for both samples. Participants answer-
ed questions on reproductive history and use of oral contra-
ception (OC) and HRT. Participants in the outpatient clinic
were also asked to state the type of residence visa to identify
and exclude non-residents. 
Participants were defined as perimenopausal if they report-
ed menstruation in the last 12 months but not in the last two
months (adapted from Brambilla’s definition (Brambilla et
al. 1994)) or if they reported menstruation in the last two
months and fulfilled at least one of three conditions: 1) de-
clared to be menopausal, 2) stated having irregular periods,
3) were currently taking menopausal hormones and were 
50 or younger. Women were classified as menopausal with a
natural menopause if they reported at least 12 months of
amenorrhea (McKinlay et al. 1992) or if they had a menstru-
ation in the last two months but were currently taking HRT
and were over 50. Participants who had had a hysterectomy
before natural menopause were classified as having a surgi-
cal menopause. Women with > 12 months of amenorrhoea
after radiotherapy or chemotherapy were classified as
menopausal for “other” reason, while those without an iden-
tified reason for menopause were considered as “unknown”
reason for menopause. 
Current HRT use was defined as ongoing HRT for a dura-
tion of at least six months. Previous OC was defined as use
of the contraceptive pill in the past for at least six months.
Age, nationality, reproductive history and characteristics of
HRT use were compared between both populations. We
performed univariate and multivariate analyses to examine
associations between HRT use and other characteristics. For
univariate analyses, we compared categorical variables with
c2 test and continuous variables with t-test. For multivariate
analyses, we used logistic regression models, adjusting for
potential confounders. The odds ratios (OR) obtained in
these models measured the magnitude of the association 
between current HRT use and several sociodemographic
and clinical characteristics in the clinic sample compared to
the general population. We used SAS software (SAS Insti-
tute, Cary, NC, USA) for the statistical analysis.
Results
Of the 185 patients who attended the clinic, 34 recently 
arrived refugees were not considered residents and were 
excluded. Of the 151 eligible patients, 15 women either 
refused to participate in the study, or could not fill in the
form because of the lack of an interpreter, while another
nine patients left the clinic before they could be appro-
ached. Of the 127 patients (84% participation rate) who
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completed the questionnaire, 20 were excluded because
they were premenopausal.
In the 1998 Bus Santé project, 337 women aged 45–65 years
(56%) responded to the postal survey, of which 96 pre-
menopausal women were excluded. We analysed the data on
the reproductive history and HRT use provided by the final
sample of 241 perimenopausal and postmenopausal women. 
General characteristics of the participants in both popula-
tions are described in Table 1. The mean age (55 years), use
of OC, menopause status, type of menopause and age by
menopause status were similar in both samples. The higher
proportion of foreigners in the clinic was the only significant
difference observed but prevalence of current HRT use
tended to be lower among women of the outpatient clinic
than in the general population (38.3% vs. 47.7%). 
On average, women started to take HRT at the age of 50,
which is close to the median age of natural menopause 
(Tab. 2). When analysed by age group, current HRT use was
definitely not restricted to the perimenopausal period, but
was distributed relatively harmoniously over the 15 years
following menopause. Similar proportions of women had
previously taken OC. We observed two significant differ-
ences in HRT use between primary care patients and the
general population. First, a higher proportion of short-term
current HRT users (one to two years) in the clinical sample
which contrasts with longer use in the community (41.5% 
vs. 18.3%). Second, a higher rate of surgical menopause 
among clinic patients than in the general population (34.4%
vs. 16.1). 
Table 3 shows results of a logistic regression expressed as 
the ratio of the odds of being a current HRT user in the clinic
(versus a never user) to the odds of being a current HRT
user in the general population according to known deter-
minants of HRT use. Multivariate analysis shows that, com-
pared to the general population, women attending the 
primary care clinic are approximately twice less likely to be
current HRT users if they had a natural menopause or were
Swiss citizens. 
Table 1 Description of participants in the outpatient clinic and in the
general population and prevalence of HRT and OC (Geneva, Switzer-
land, 1998)
Characteristic Clinic General P-value
n = 107 Population
n = 241
Age (mean +SD) 55.5 (+ 5.8) 55.3 (+ 5.3) 0.8
Age distribution (%)
45–49 23.4 14.1 0.06
50–54 18.7 30.3
55–59 32.7 30.3
60–65 25.2 25.3
Swiss Nationality (%)
yes 57.0 76.4 0.001
no 43.0 23.6
Menopause status (%) 
perimenopausal 29.0 22.8 0.2
postmenopausal 71.0 77.2
Type of menopause (%)a
natural menopause 70.7 75.2 0.4
surgical menopause 25.3 22.0
other 2.7 2.8
unknown 1.3 0.0
Age by menopause  
status (mean yrs +SD)
perimenopause 49.4 (+ 3.4) 50.5 (+ 4.1) 0.2
postmenopause 58.0 (+ 4.5) 56.8 (+ 4.7) 0.05
Contraceptive pill (%)
ever use 56.1 58.5 0.7
Hormone replacement 
therapy (%)
current use 38.3 47.7 0.1
past use 10.3 5.8
never use 51.4 46.5
a n = 75 in the clinic and n = 182 in the population survey (postmeno-
pausal women only)
Table 2 Characteristics of current HRT users in the clinic and in the 
general population (Geneva, Switzerland, 1998)
Characteristic Clinic General P-value
n=41 Population
n=115
Mean age (+SD) 56.4 (+5.3) 56.4 (+4.8) 0.9
Age of HRT initiation 50.5 (+5.6) 50.2 (+4.2) 0.8
(mean+SD)
Swiss nationality (%)
yes 46.3 73.9 0.0013
no 53.7 26.1
HRT duration
mean (+SD) 5.5 (+ 5.4) 6.2 (+ 3.8) 0.5
HRT duration by age 
group (mean+SD)
45–49 years 1.0 (+0.6) 2.4 (+1.4) 0.04
50–54 years 4.2 (+3.9) 4.5 (+3.0) 0.8
55–59 years 6.4 (+4.9) 6.0 (+3.3) 0.8
60–65 years 8.0 (+7.0) 8.9 (+3.6) 0.7
HRT duration (%)
1–2 years 41.5 18.3 0.01
3–4 years 19.5 25.2
> 5 years 39.0 56.5
Menopause status (%)
perimenopause 19.5 17.4 0.8
postmenopause 80.5 82.6
Type of postmeno-
pause (%)
natural menopause 59.4 81.7 0.04
surgical menopause 34.4 16.1
other 6.3 2.2
Prior use of oral 
contraception (%)
yes 61.0 62.6 0.9
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Discussion
This comparative study between clinical and epidemiolog-
ical data is an innovative approach to assessing differences 
in medical practice in the hospital versus the community.
Differences observed in health behaviour between women
in clinical practice and in the community can be considered
an indirect indicator of the residents’ approach to HRT
counselling. 
Prevalence of current HRT use in the outpatient clinic was
38.3 %, which was lower, although not significantly so, than
in the general population. Clinic women with a surgical
menopause used HRT significantly more often than women
in the general population with the same characteristics.
Also, current users in clinical practice used HRT for a
shorter period (one to two years) than in the community and
were less likely to be Swiss.
To our knowledge, this is the first report that directly com-
pares the prevalence and the application of a clinical pre-
ventive guideline in a clinical context with HRT use in the
general population. This is possible because of the identical
methodology applied in both surveys. Characteristics of
HRT use among women in medical care can therefore be 
directly compared with those of women living in the com-
munity, instead of solely being compared with unrelated
clinical and epidemiological data.
It is important to remember that this study was conducted 
in the pre-WHI (Women’s Health Initiative) era when long-
term HRT use was recommended for the prevention of
chronic disease. Since then evidence has shown that HRT
carries more risks than benefits and the U.S. Preventive 
Services Task Force (2002) now recommends against HRT
use for the prevention of chronic conditions.
In 1998, the prevalence of HRT in the clinical sample 
(38.3%) could be considered high when compared to most
recent studies which showed that in clinical practice uptake
was rarely higher than 30% with the exception of one 
study which showed a prevalence of 60% (Stafford et al.
1997; Ghali et al. 1997; Wise et al. 1999; Levy et al. 2003).
However, when compared to the prevalence in the popula-
tion sample (47.7%), current HRT use in the clinic appeared
to be rather low. The fact that prevalence in the clinical 
sample was not superior to prevalence in the population is
interesting since results from previous reports suggested 
that women in a medical setting used more hormones than
the general population (Johannes et al. 1994; MacLennan 
et al. 1993; Ringa & Jaussent, 1999; Zhang et al. 1999). 
There may be several reasons for the tendency to low 
HRT use in our clinical sample. An important contributing
factor to lower HRT uptake in the clinic compared to the
community was probably the difference in socio-economic
Table 3 Prevalence and Odds Ratio of current HRT use (versus never use) in the clinic and in the general population by different characteristics
(Geneva, Switzerland, 1998)
Characteristic Current HRT use ORa CI95%
Clinic General population
N % N %
Age groups
45–49 23 26.1 32 28.1 0.7 (0.2–2.5)
50–54 19 42.1 70 47.1 0.8 (0.3–2.2)
55–59 30 56.7 69 56.5 1.0 (0.4–2.4)
60–65 24 41.7 56 60.7 0.4 (0.2–1.2)
Nationality
Swiss 55 34.6 172 49.4 0.5 (0.2-0.9)
foreign 41 53.7 55 54.6 1.0 (0.5-2.4)
Menopausal status
postmenopausal 29 27.6 52 38.5 0.8 (0.4–1.4)
perimenopausal 67 49.3 175 54.3 0.8 (0.3–2.1)
Type of menopause
natural menopause 47 40.4 126 60.3 0.4 (0.2–0.9)
surgical menopause 16 68.8 40 37.5 3.7 (1.0–12.9)
Prior oral contraception
yes 54 46.3 131 55.0 0.7 (0.4–1.4)
no 42 38.1 96 44.8 0.7 (0.3–1.5)
OR = odds ratio; CI = confidence interval.
a simultaneously adjusted for all other variables in the table.
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status and cultural background between the two samples.
Even though migrant patients were excluded from the 
clinic sample, patients in the clinic had a lower socio-eco-
nomic status which had consistently been associated with
lower HRT use (Finley et al. 2001; Brett & Madans, 1997; 
Johannes et al. 1994; Derby et al. 1993).
Medical speciality played an important part in doctors’
counselling and prescribing practices regarding HRT. In
Switzerland, gynaecologists work as primary care providers
for women’s health. This explains why all participants who
took HRT in the outpatient clinic stated that the treatment
was prescribed by their gynaecologist (results not shown).
Gynaecologists were generally more favourable to HRT as 
a treatment for menopausal symptoms and for disease pre-
vention than primary care physicians (Hemminki et al. 1993;
Jolleys & Olesen 1996; Levy et al. 2003). Thus, the level of
HRT use in the population survey could very well have re-
flected the high level of HRT prescribing among Swiss gyn-
aecologists. This implies that clinic patients visited less often
a gynaecologist. Also, residents in the clinic could have been
influenced by European authors who favoured HRT less
strongly than their American counterparts (Posthuma et al.
1994; Khaw 1998). Furthermore, residents may have been
more cautious in recommending long-term HRT use as they
were exposed to a critical and evidence-based approach to
preventive interventions during their residency training.
Practising physicians in the community may have been 
more influenced by pro-HRT Swiss gynaecological opinion
leaders.
In our study, current HRT users in medical care were more
likely to have a surgical menopause than current users in the
general population. This result shows that counselling by
residents in the outpatient clinic focused on women with a
hysterectomy, which followed the American College of
Physicians’ recommendations of the time (American Col-
lege of Physicians 1992; U.S. Preventive Services Task Force
1996). Surgical menopause had been universally associated
with HRT use (Johannes et al. 1994; Keating et al. 1999;
Moorhead et al. 1997; MacLennan et al. 1993; Taffe et al.
1997; Harris et al. 1999). 
The study also shows that a higher proportion of current
users in the clinic took HRT for short periods than in the
general population. 
Current HRT users were less likely to be Swiss in the clinical
sample than in the general population. It is likely that Swiss
patients in the clinic came from a lower socio-economic
background and therefore presented a lower uptake than
Swiss women from the general population. 
In general, apart from a significantly lower proportion of
Swiss patients in the clinic, the two study groups are similar
in relation to age and menopause characteristics. When pat-
terns of HRT use are compared between the two popula-
tions, patients in the clinic are taking HRT differently. They
tend to use less HRT, for shorter periods and preferably
when they have a surgical menopause. The different pattern
of HRT use emphasized by this comparative study is an indi-
cator of the residents’ clinical practice. 
Our study is limited by the smaller sample in the outpatient
clinic and the relatively low participation rate (56%) of
women aged 45–65 years in the community sample. Since
29.3% of non-responders to the epidemiological survey were
smokers versus 18.3% of participants (data not shown), the
prevalence of HRT in the community sample could have
been overestimated due to a selection bias towards a health-
ier lifestyle (Hemminki et al. 1993). However, smoking was
not associated with current HRT use in the general popula-
tion (results not shown).
The epidemiological survey provided data on average or
“typical” behaviour in relation to HRT use in the commun-
ity. We used this information to critically assess clinical prac-
tice in the same geographical area. We think that similar
comparisons would be useful in other fields of medicine 
such as diabetes care or control of coronary heart disease
risk factors. 
In conclusion, our report shows that prevalence of HRT use
in a Swiss academic general internal medicine outpatient
clinic was relatively low compared to use in the community.
This can be explained by socio-economic and medical 
factors. Compared to patterns of use in the community, 
HRT use in the clinic didn’t fully comply with prevailing re-
commendations on the prevention of chronic disease. Our 
study proposes an innovative approach to analysing clinical
practice by providing a “population perspective” which
gives clinicians the opportunity to critically assess their own
practice. This method could be applied to other fields of 
prevention.
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Zusammenfassung
Gebrauch der Hormonsubstitutionstherapie in der Menopause:
Vergleich zwischen Hausarzt-Patientinnen und der Allgemein-
bevölkerung
Fragestellung: Ziel der Studie ist der Vergleich zwischen der
Häufigkeit und Verschreibungsmuster für Hormonsubstitutions-
therapie (HRT) zwischen Hausarzt-Patientinnen and der loka-
len Allgemeinbevölkerung. 
Methoden: Vergleich zwischen Daten einer 1998 durchgeführ-
ten Fragebogen-Umfrage mit 107 peri- und postmenopausalen
Patientinnen einer universitären Poliklinik mit ähnlichen Daten
einer Stichprobe (n = 240) einer fortlaufenden jährlichen epi-
demiologischen Bevölkerungsumfrage.
Ergebnisse: Mittleres Alter, Menopausestatus, Alter bei Beginn
der HRT sowie früherer Gebrauch der Kontrazeptionspille wa-
ren in beiden Gruppen ähnlich. Gegenwärtiger Gebrauch von
HRT war niedriger bei Patientinnen der Poliklinik. HRT-Benut-
zerinnen der Poliklinik hatten häufiger eine chirurgische Meno-
pause (34,4% vs. 16,1%; p=0,04) und eine geringere Dauer der
HRT als die lokale Allgemeinbevölkerung. Die Unterschiede
blieben auch nach multivariaten Analysen signifikant. 
Schlussfolgerung: Im Vergleich zur Allgemeinbevölkerung
wurde die HRT in der Poliklinik weniger eingesetzt als dies die
damals gültigen Empfehlungen vorsahen. Diese Studie ist ein
Beispiel dafür, wie der Vergleich zwischen Patientinnen einer
Poliklinik und einer lokalen epidemiologischen Studie mit-
helfen kann, Versorgungsaspekte in Public Health besser zu
verstehen.
Résumé
Utilisation de l’hormonothérapie de substitution à la méno-
pause: une comparaison entre des patientes en médecine de
premier recours et la population générale
Objectifs: Comparer la fréquence et l’utilisation du traitement
hormonal de substitution (THS) en médecine de premier recours
et dans la population générale.
Méthodes: Etude transversale par questionnaire de 107 pa-
tientes péri- et post ménopausées dans un centre universitaire
de premiers recours en novembre et décembre 1998. Compa-
raison avec des données similaires d’un échantillon (n=241)
d’une étude épidémiologique annuelle représentative de la
population générale.
Résultats: La fréquence d’utilisation antérieure d’une contra-
ception orale était semblable dans les deux groupes. L’utilisa-
tion actuelle du THS avait tendance à être moins importante
chez des femmes du centre universitaire que dans la population
générale. Les utilisatrices du THS dans le centre avaient plus 
souvent une ménopause chirurgicale (34,4% contre 16,1%,
p=0,04) et utilisaient les hormones pendant une durée plus
courte que dans la population. Ces différences restaient signi-
ficatives après analyse multivariée.
Conclusions: L’utilisation de THS dans le centre universitaire de
médecine de premier recours était plus restrictive que dans la
population générale par rapport aux recommandations scienti-
fiques de l’époque sur la prescription de THS. Cette comparai-
son directe entre des patients suivis par des médecins et la pop-
ulation générale est utile pour analyser la pratique médicale.
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